Drug Patents Expiring in 2032

1. Abilify Mycite Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10517507 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jun, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: NA

Dosage: TABLET

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

2. Abraxane patent expiration

ABRAXANE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393318 BRISTOL-MYERS Methods of treating cancer
Mar, 2032

(7 years from now)

US9597409 BRISTOL-MYERS Methods of treating cancer
Mar, 2032

(7 years from now)

US9393318

(Pediatric)

BRISTOL-MYERS Methods of treating cancer
Sep, 2032

(7 years from now)

US9597409

(Pediatric)

BRISTOL-MYERS Methods of treating cancer
Sep, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-658) Oct 11, 2015
New Indication(I-676) Sep 06, 2016
Orphan Drug Exclusivity(ODE) Sep 06, 2020
Orphan Drug Exclusivity(ODE-52) Sep 06, 2020
M(M-14) Dec 06, 2022
Pediatric Exclusivity(PED) Jun 06, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of lung cancer

Dosage: POWDER

How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage

ABRAXANE family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Acetadote patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722738 CUMBERLAND PHARMS Acetycysteine compositions and methods of use thereof
Apr, 2032

(7 years from now)




Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: INJECTABLE

How can I launch a generic of ACETADOTE before it's drug patent expiration?
More Information on Dosage

ACETADOTE family patents

Family Patents

4. Adlyxin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511193 SANOFI-AVENTIS US Assembly and indicator for a drug delivery device
Jan, 2032

(7 years from now)

US9440029 SANOFI-AVENTIS US Drive mechanism for a drug delivery device and drug delivery device
Jan, 2032

(7 years from now)

US9072836 SANOFI-AVENTIS US Drive mechanism for a drug delivery device and drug delivery device
Mar, 2032

(7 years from now)

US9821032 SANOFI-AVENTIS US Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
May, 2032

(7 years from now)

US9408893 SANOFI-AVENTIS US Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 27, 2021

Drugs and Companies using LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 27 July, 2016

Treatment: Combination treatment with insulin glargine with or without metformin for improvement of glycemic control in type 2 diabetes mellitus patients; Combination treatment with a glitazone for improvement o...

Dosage: SOLUTION

More Information on Dosage

ADLYXIN family patents

Family Patents

5. Adzenys Er patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9017731 NEOS THERAPS INC Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(7 years from now)

US9265737 NEOS THERAPS INC Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles
Jun, 2032

(7 years from now)

US8709491 NEOS THERAPS INC Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(7 years from now)




Drugs and Companies using AMPHETAMINE ingredient

Market Authorisation Date: 15 September, 2017

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

ADZENYS ER family patents

Family Patents

6. Adzenys Xr-odt patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9017731 NEOS THERAPS Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(7 years from now)

US9265737 NEOS THERAPS Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles
Jun, 2032

(7 years from now)

US8709491 NEOS THERAPS Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(7 years from now)

US9839619 NEOS THERAPS Method for treating ADD or ADHD comprising administering amphetamine complexed with ion-exchange resin particles
Jun, 2032

(7 years from now)




Drugs and Companies using AMPHETAMINE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE

How can I launch a generic of ADZENYS XR-ODT before it's drug patent expiration?
More Information on Dosage

ADZENYS XR-ODT family patents

Family Patents

7. Afrezza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8499757 MANNKIND Dry powder inhaler and system for drug delivery
Feb, 2032

(7 years from now)

US8636001 MANNKIND Dry powder inhaler and system for drug delivery
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 27, 2017

Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient

Market Authorisation Date: 27 June, 2014

Treatment: NA

Dosage: POWDER

More Information on Dosage

AFREZZA family patents

Family Patents

8. Airduo Digihaler patent expiration

AIRDUO DIGIHALER IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(7 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(7 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(7 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(7 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

9. Airduo Respiclick patent expiration

AIRDUO RESPICLICK IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(7 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(7 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(7 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(7 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2020
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

More Information on Dosage

AIRDUO RESPICLICK family patents

Family Patents

10. Akynzeo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10717721 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(7 years from now)

US9908907 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(7 years from now)

US9403772 HELSINN HLTHCARE 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
May, 2032

(7 years from now)

US8426450 HELSINN HLTHCARE Substituted 4-phenyl pyridines having anti-emetic effect
May, 2032

(7 years from now)

US11312698 HELSINN HLTHCARE Fosnetupitant chloride hydrochloride having improved stability
May, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10208073 HELSINN HLTHCARE Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator
May, 2032

(7 years from now)

US8895586 HELSINN HLTHCARE Methods of treating emesis
May, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: 19 April, 2022

Market Authorisation Date: 19 April, 2018

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER; SOLUTION

How can I launch a generic of AKYNZEO before it's drug patent expiration?
More Information on Dosage

AKYNZEO family patents

Family Patents

11. Alecensa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9365514 HOFFMANN-LA ROCHE Composition comprising tetracyclic compound
Mar, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-756) Nov 06, 2020
New Chemical Entity Exclusivity(NCE) Dec 11, 2020
Orphan Drug Exclusivity(ODE-105) Dec 11, 2022
Orphan Drug Exclusivity(ODE) Nov 06, 2024
Orphan Drug Exclusivity(ODE-159) Nov 06, 2024
New Indication(I-947) Apr 18, 2027
Orphan Drug Exclusivity(ODE-477) Apr 18, 2031

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

NCE-1 date: 12 December, 2019

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE

How can I launch a generic of ALECENSA before it's drug patent expiration?
More Information on Dosage

ALECENSA family patents

Family Patents

12. Aliqopa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10383876 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Mar, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636344 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
Mar, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 14, 2022
Orphan Drug Exclusivity(ODE) Sep 14, 2024
Orphan Drug Exclusivity(ODE-155) Sep 14, 2024

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

NCE-1 date: 14 September, 2021

Market Authorisation Date: 14 September, 2017

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER

More Information on Dosage

ALIQOPA family patents

Family Patents

13. Alkindi Sprinkle patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717740 ETON Treatment of adrenal insufficiency
Nov, 2032

(7 years from now)




Drugs and Companies using HYDROCORTISONE ingredient

Market Authorisation Date: 29 September, 2020

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE

More Information on Dosage

ALKINDI SPRINKLE family patents

Family Patents

14. Amvuttra patent expiration

AMVUTTRA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9399775 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(7 years from now)

US10570391 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 13, 2027
Orphan Drug Exclusivity(ODE-212) Jun 13, 2029

Drugs and Companies using VUTRISIRAN SODIUM ingredient

NCE-1 date: 13 June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION

More Information on Dosage

AMVUTTRA family patents

Family Patents

15. Aptiom patent expiration

Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750747 SUMITOMO PHARMA AM Treatments involving eslicarbazepine acetate or eslicarbazepine
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-150) Aug 27, 2018
New Indication(I-715) Aug 27, 2018
New Chemical Entity Exclusivity(NCE) Nov 08, 2018

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

NCE-1 date: 08 November, 2017

Market Authorisation Date: 08 November, 2013

Treatment: Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures

Dosage: TABLET

How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage

APTIOM family patents

Family Patents

16. Aristada patent expiration

ARISTADA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10226458 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters
Mar, 2032

(7 years from now)

US9034867 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 05, 2020

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

NCE-1 date: 06 October, 2019

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

ARISTADA family patents

Family Patents

17. Armonair Digihaler patent expiration

ARMONAIR DIGIHALER IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(7 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(7 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(7 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(7 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

18. Armonair Respiclick patent expiration

ARMONAIR RESPICLICK IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(7 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(7 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(7 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(7 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2020
New Patient Population(NPP) Jul 09, 2024
New Strength(NS) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

ARMONAIR RESPICLICK family patents

Family Patents

19. Avycaz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9284314 ABBVIE Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(7 years from now)

US9695122 ABBVIE Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(7 years from now)

US8969566 ABBVIE Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-738) Jun 22, 2019
New Chemical Entity Exclusivity(NCE) Feb 25, 2020
Generating Antibiotic Incentives Now(GAIN) Feb 25, 2025
New Patient Population(NPP) Dec 20, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 26 February, 2024

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: POWDER

More Information on Dosage

AVYCAZ family patents

Family Patents

20. Azstarys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079928 COMMAVE THERAP Methylphenidate-oxoacid conjugates, processes of making and using the same
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 07, 2026

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

NCE-1 date: 07 May, 2025

Market Authorisation Date: 07 May, 2021

Treatment: NA

Dosage: CAPSULE

More Information on Dosage

AZSTARYS family patents

Family Patents

21. Belbuca patent expiration

Can you believe BELBUCA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9901539 BDSI Transmucosal drug delivery devices for use in chronic pain relief
Dec, 2032

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 23, 2018

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 October, 2015

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: FILM

How can I launch a generic of BELBUCA before it's drug patent expiration?
More Information on Dosage

BELBUCA family patents

Family Patents

22. Belviq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9169213 EISAI INC Method of weight management
Dec, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 27 June, 2012

Treatment: Use of belviq (lorcaserin hydrochloride) for chronic weight management by treating obesity in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week...

Dosage: TABLET

How can I launch a generic of BELVIQ before it's drug patent expiration?
More Information on Dosage

BELVIQ family patents

Family Patents

23. Belviq Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9169213 EISAI INC Method of weight management
Dec, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 15 July, 2016

Treatment: Use of lorcaserin hydrochloride for chronic weight management by treating obesity in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of tr...

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of BELVIQ XR before it's drug patent expiration?
More Information on Dosage

BELVIQ XR family patents

Family Patents

24. Bijuva patent expiration

BIJUVA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11865179 MAYNE PHARMA Progesterone formulations having a desirable PK profile
Nov, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10052386 MAYNE PHARMA Progesterone formulations
Nov, 2032

(7 years from now)

US11033626 MAYNE PHARMA Progesterone formulations having a desirable pk profile
Nov, 2032

(7 years from now)

US9006222 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US10806740 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US8993548 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US11793819 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US8846649 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US8846648 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US9114146 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US9301920 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US11103516 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US11110099 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US9114145 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US8933059 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US10675288 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US8987237 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US11166963 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US8993549 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US11529360 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US8633178 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US10639375 MAYNE PHARMA Progesterone formulations
Nov, 2032

(7 years from now)

US10206932 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)

US11103513 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 28, 2021

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Market Authorisation Date: 28 December, 2021

Treatment: Treatment of menopause symptoms, including vasomotor symptoms

Dosage: CAPSULE

How can I launch a generic of BIJUVA before it's drug patent expiration?
More Information on Dosage

BIJUVA family patents

Family Patents

25. Biktarvy patent expiration

BIKTARVY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(7 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 18, 2022
New Chemical Entity Exclusivity(NCE) Feb 07, 2023
M(M-82) Feb 24, 2024
Orphan Drug Exclusivity(ODE-256) Jun 18, 2026
New Indication(I-942) Feb 23, 2027
M(M-305) Apr 24, 2027
Orphan Drug Exclusivity(ODE-378) Oct 07, 2028
Orphan Drug Exclusivity(ODE-468) Feb 23, 2031

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 07 February, 2022

Market Authorisation Date: 07 October, 2021

Treatment: Treatment of hiv infection

Dosage: TABLET

How can I launch a generic of BIKTARVY before it's drug patent expiration?
More Information on Dosage

BIKTARVY family patents

Family Patents

26. Bortezomib patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962572 FRESENIUS KABI USA Bortezomib formulations
Nov, 2032

(7 years from now)




Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 06 November, 2017

Treatment: NA

Dosage: POWDER

More Information on Dosage

BORTEZOMIB family patents

Family Patents

27. Braftovi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9763941 ARRAY BIOPHARMA INC Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Nov, 2032

(7 years from now)

US10258622 ARRAY BIOPHARMA INC Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
Nov, 2032

(7 years from now)

US9387208 ARRAY BIOPHARMA INC Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-826) Apr 08, 2023
New Chemical Entity Exclusivity(NCE) Jun 27, 2023
Orphan Drug Exclusivity(ODE-194) Jun 27, 2025
New Indication(I-928) Oct 11, 2026
Orphan Drug Exclusivity(ODE-445) Oct 11, 2030

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Treatment of melanoma; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, a...

Dosage: CAPSULE

How can I launch a generic of BRAFTOVI before it's drug patent expiration?
More Information on Dosage

BRAFTOVI family patents

Family Patents

28. Brenzavvy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8987323 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
May, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 20, 2028

Drugs and Companies using BEXAGLIFLOZIN ingredient

NCE-1 date: 20 January, 2027

Market Authorisation Date: 20 January, 2023

Treatment: NA

Dosage: TABLET

More Information on Dosage

BRENZAVVY family patents

Family Patents

29. Brixadi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11110084 BRAEBURN Opioid formulations
Jul, 2032

(7 years from now)

US10912772 BRAEBURN Opioid formulations
Jul, 2032

(7 years from now)

US9937164 BRAEBURN Opioid formulations
Jul, 2032

(7 years from now)

US11135215 BRAEBURN Opioid formulations
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 23, 2026

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 23 May, 2023

Treatment: A method of administering an opioid maintenance treatment comprising buprenorphine; A method of administering an opioid maintenance treatment comprising buprenorphine. a method of treating opioid with...

Dosage: SOLUTION, EXTENDED RELEASE

More Information on Dosage

BRIXADI family patents

Family Patents

30. Bunavail patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703177 BDSI Abuse-resistant mucoadhesive devices for delivery of buprenorphine
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 06, 2017

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: NA

Dosage: FILM

How can I launch a generic of BUNAVAIL before it's drug patent expiration?
More Information on Dosage

BUNAVAIL family patents

Family Patents

31. Cabometyx patent expiration

CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11298349 EXELIXIS INC Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 29, 2017
New Product(NP) Apr 25, 2019
New Indication(I-760) Dec 19, 2020
New Indication(I-792) Jan 14, 2022
New Indication(I-854) Jan 22, 2024
New Indication(I-873) Sep 17, 2024
Orphan Drug Exclusivity(ODE-227) Jan 14, 2026
Orphan Drug Exclusivity(ODE-375) Sep 17, 2028

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 25 April, 2016

Treatment: NA

Dosage: TABLET

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

32. Caldolor patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072710 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(7 years from now)

US11806400 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(7 years from now)

US9072661 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 11, 2012
New Dosing Schedule(D-152) Nov 20, 2018
M(M-128) Nov 19, 2024
New Patient Population(NPP) May 11, 2026

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 11 June, 2009

Treatment: Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of making aqueous composition and treating pain, inflammation, ...

Dosage: SOLUTION

More Information on Dosage

CALDOLOR family patents

Family Patents

33. Calquence patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(7 years from now)

US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 31, 2022
New Indication(I-817) Nov 21, 2022
Orphan Drug Exclusivity(ODE-175) Oct 31, 2024
Orphan Drug Exclusivity(ODE-274) Nov 21, 2026

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: 31 October, 2021

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination wi...

Dosage: TABLET

More Information on Dosage

CALQUENCE family patents

Family Patents

34. Calquence patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(7 years from now)

US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 31, 2022
New Indication(I-817) Nov 21, 2022
Orphan Drug Exclusivity(ODE-175) Oct 31, 2024
Orphan Drug Exclusivity(ODE-274) Nov 21, 2026

Drugs and Companies using ACALABRUTINIB ingredient

NCE-1 date: 31 October, 2021

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia

Dosage: CAPSULE

How can I launch a generic of CALQUENCE before it's drug patent expiration?
More Information on Dosage

CALQUENCE family patents

Family Patents

35. Caspofungin Acetate patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636407 FRESENIUS KABI USA Caspofungin acetate formulations
Dec, 2032

(8 years from now)




Drugs and Companies using CASPOFUNGIN ACETATE ingredient

Market Authorisation Date: 30 December, 2016

Treatment: NA

Dosage: POWDER

More Information on Dosage

CASPOFUNGIN ACETATE family patents

Family Patents

36. Cetylev patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427421 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine
May, 2032

(7 years from now)

US8747894 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine
May, 2032

(7 years from now)

US9561204 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine
May, 2032

(7 years from now)




Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 29 January, 2016

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: TABLET, EFFERVESCENT

More Information on Dosage

CETYLEV family patents

Family Patents

37. Cometriq patent expiration

COMETRIQ's oppositions filed in EPO
Can you believe COMETRIQ received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717720 EXELIXIS Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(7 years from now)

US11298349 EXELIXIS Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 29, 2017
Orphan Drug Exclusivity(ODE) Nov 29, 2019
Orphan Drug Exclusivity(ODE-33) Nov 29, 2019

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 29 November, 2012

Treatment: NA

Dosage: CAPSULE

More Information on Dosage

COMETRIQ family patents

Family Patents

38. Contrave patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248123 NALPROPION Methods of providing weight loss therapy in patients with major depression
Jan, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Sep 10, 2017

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

39. Copiktra patent expiration

Can you believe COPIKTRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46621 SECURA Processes for preparing isoquinolinones and solid forms of isoquinolinones
May, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11312718 SECURA Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
Jan, 2032

(7 years from now)

US9840505 SECURA Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
Jan, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 24, 2023
Orphan Drug Exclusivity(ODE-208) Sep 24, 2025
Orphan Drug Exclusivity(ODE-209) Sep 24, 2025

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: 24 September, 2022

Market Authorisation Date: 24 September, 2018

Treatment: For the treatment of patients with follicular lymphoma (fl)

Dosage: CAPSULE

More Information on Dosage

COPIKTRA family patents

Family Patents

40. Cotempla Xr-odt patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072680 NEOS THERAPS INC Compositions comprising methylphenidate complexed with ion-exchange resin particles
Jun, 2032

(7 years from now)

US9089496 NEOS THERAPS INC Compositions comprising methylphenidate complexed with ion-exchange resin particles
Jun, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 19, 2020

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 19 June, 2017

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE

How can I launch a generic of COTEMPLA XR-ODT before it's drug patent expiration?
More Information on Dosage

COTEMPLA XR-ODT family patents

Family Patents

41. Cycloset patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9993474 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US10688094 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US9192576 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US11000522 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US9700555 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US8613947 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US9522117 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US8431155 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US11666567 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 05, 2012

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Market Authorisation Date: 05 May, 2009

Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 21, 28, ...

Dosage: TABLET

More Information on Dosage

CYCLOSET family patents

Family Patents

42. Daybue patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9212204 ACADIA PHARMS INC Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid
Jan, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 10, 2028
Orphan Drug Exclusivity(ODE-425) Mar 10, 2030

Drugs and Companies using TROFINETIDE ingredient

NCE-1 date: 11 March, 2027

Market Authorisation Date: 10 March, 2023

Treatment: Treatment of rett syndrome or a symptom thereof

Dosage: SOLUTION

More Information on Dosage

DAYBUE family patents

Family Patents

43. Defitelio patent expiration

DEFITELIO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11236328 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(7 years from now)

US11746348 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(7 years from now)

US11085043 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 30, 2021
Orphan Drug Exclusivity(ODE) Mar 30, 2023
Orphan Drug Exclusivity(ODE-112) Mar 30, 2023

Drugs and Companies using DEFIBROTIDE SODIUM ingredient

NCE-1 date: 30 March, 2020

Market Authorisation Date: 30 March, 2016

Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic st...

Dosage: SOLUTION

More Information on Dosage

DEFITELIO family patents

Family Patents

44. Descovy patent expiration

DESCOVY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(7 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 28, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Indication(I-812) Oct 03, 2022
Orphan Drug Exclusivity(ODE-284) Sep 28, 2024
Orphan Drug Exclusivity(ODE-285) Sep 28, 2024
Orphan Drug Exclusivity(ODE-457) Jan 07, 2029

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 07 January, 2022

Treatment: Treatment of hiv-1 infection; Treatment of hiv infection

Dosage: TABLET

How can I launch a generic of DESCOVY before it's drug patent expiration?
More Information on Dosage

DESCOVY family patents

Family Patents

45. Detectnet patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10383961 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors
Aug, 2032

(7 years from now)

US11160888 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors
Aug, 2032

(7 years from now)

US10159759 RADIOMEDIX Pet tracer for imaging of neuroendocrine tumors
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 03, 2025
Orphan Drug Exclusivity(ODE-317) Sep 03, 2027

Drugs and Companies using COPPER CU-64 DOTATATE ingredient

NCE-1 date: 03 September, 2024

Market Authorisation Date: 03 September, 2020

Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients

Dosage: SOLUTION

More Information on Dosage

DETECTNET family patents

Family Patents

46. Dexilant patent expiration

Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233103 TAKEDA PHARMS USA Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
Mar, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 30, 2012
Pediatric Exclusivity(PED) Jul 30, 2012
New Patient Population(NPP) Jul 08, 2019

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions

Dosage: CAPSULE, DELAYED RELEASE

How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage

DEXILANT family patents

Family Patents

47. Dexycu Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799642 EYEPOINT PHARMS Dose guides for injection syringe
May, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 09, 2021

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 09 February, 2018

Treatment: NA

Dosage: SUSPENSION

More Information on Dosage

DEXYCU KIT family patents

Family Patents

48. Dilaudid patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731082 FRESENIUS KABI USA Drug container
Apr, 2032

(7 years from now)




Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 January, 2020

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of DILAUDID before it's drug patent expiration?
More Information on Dosage

DILAUDID family patents

Family Patents

49. Dilaudid-hp patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731082 FRESENIUS KABI USA Drug container
Apr, 2032

(7 years from now)




Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 January, 2020

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of DILAUDID-HP before it's drug patent expiration?
More Information on Dosage

DILAUDID-HP family patents

Family Patents

50. Duvyzat patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9421184 ITALFARMACO SPA Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy
Feb, 2032

(7 years from now)

US9867799 ITALFARMACO SPA Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 21, 2029
Orphan Drug Exclusivity(ODE-473) Mar 21, 2031

Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient

NCE-1 date: 21 March, 2028

Market Authorisation Date: 21 March, 2024

Treatment: A method for the treatment of duchenne muscular dystrophy (dmd) using givinostat

Dosage: SUSPENSION

More Information on Dosage

DUVYZAT family patents

Family Patents

51. Duzallo patent expiration

DUZALLO's oppositions filed in EPO
Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8546436 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Feb, 2032

(7 years from now)




Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: NA

Dosage: TABLET

More Information on Dosage

DUZALLO family patents

Family Patents

52. Epaned Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9968553 AZURITY Enalapril compositions
Nov, 2032

(7 years from now)

US8568747 AZURITY Enalapril compositions
Nov, 2032

(7 years from now)

US9855214 AZURITY Enalapril compositions
Nov, 2032

(7 years from now)

US8778366 AZURITY Enalapril compositions
Nov, 2032

(7 years from now)




Drugs and Companies using ENALAPRIL MALEATE ingredient

Market Authorisation Date: 13 August, 2013

Treatment: Treatment of heart failure; Method of treating left ventricular dysfunction

Dosage: FOR SOLUTION

How can I launch a generic of EPANED KIT before it's drug patent expiration?
More Information on Dosage

EPANED KIT family patents

Family Patents

53. Epclusa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(7 years from now)

US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(7 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 28, 2021
New Dosing Schedule(D-177) Nov 15, 2022
New Patient Population(NPP) Mar 19, 2023
New Strength(NS) Mar 19, 2023
M(M-264) Jul 14, 2023
M(M-277) Apr 27, 2025
Orphan Drug Exclusivity(ODE-293) Mar 19, 2027
Orphan Drug Exclusivity(ODE-376) Jun 10, 2028
Pediatric Exclusivity(PED) Dec 10, 2028

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

NCE-1 date: 11 December, 2027

Market Authorisation Date: 19 March, 2020

Treatment: For the treatment of hepatitis c

Dosage: TABLET; PELLETS

More Information on Dosage

EPCLUSA family patents

Family Patents

54. Epsolay patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687465 GALDERMA LABS LP Compositions for the treatment of rosacea
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 22, 2025

Drugs and Companies using BENZOYL PEROXIDE ingredient

Market Authorisation Date: 22 April, 2022

Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older

Dosage: CREAM

More Information on Dosage

EPSOLAY family patents

Family Patents

55. Evotaz patent expiration

EVOTAZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 BRISTOL Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2017

Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 29 January, 2015

Treatment: NA

Dosage: TABLET

How can I launch a generic of EVOTAZ before it's drug patent expiration?
More Information on Dosage

EVOTAZ family patents

Family Patents

56. Evzio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8627816 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2032

(7 years from now)




Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

EVZIO family patents

Family Patents

57. Evzio (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8627816 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2032

(7 years from now)




Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

58. Fetzima patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8865937 ABBVIE Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
May, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
NCE*(NCE*) Jul 25, 2018
M(M-249) Oct 07, 2022
M(M-304) Mar 24, 2026

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of FETZIMA before it's drug patent expiration?
More Information on Dosage

FETZIMA family patents

Family Patents

59. Fiasp Flextouch patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 29, 2020
New Patient Population(NPP) Dec 19, 2022

Drugs and Companies using INSULIN ASPART ingredient

Market Authorisation Date: 29 September, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

FIASP FLEXTOUCH family patents

Family Patents

60. Firdapse patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11060128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(7 years from now)

US11268128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(7 years from now)

US11274332 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(7 years from now)

US11274331 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 28, 2023
New Patient Population(NPP) Sep 29, 2025
Orphan Drug Exclusivity(ODE-223) Nov 28, 2025

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

NCE-1 date: 28 November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET

How can I launch a generic of FIRDAPSE before it's drug patent expiration?
More Information on Dosage

FIRDAPSE family patents

Family Patents

61. Firmagon patent expiration

FIRMAGON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10695398 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(7 years from now)

US9415085 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(7 years from now)

US11826397 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(7 years from now)

US11766468 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 24, 2013

Drugs and Companies using DEGARELIX ACETATE ingredient

NCE-1 date: 24 December, 2012

Market Authorisation Date: 24 December, 2008

Treatment: Method of treating prostate cancer; Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect

Dosage: POWDER

How can I launch a generic of FIRMAGON before it's drug patent expiration?
More Information on Dosage

FIRMAGON family patents

Family Patents

62. Flyrcado patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687571 GE HLTHCARE Stabilization of radiopharmaceutical compositions using ascorbic acid
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 27, 2029

Drugs and Companies using FLURPIRIDAZ F-18 ingredient

NCE-1 date: 27 September, 2028

Market Authorisation Date: 27 September, 2024

Treatment: Method of positron emission tomography (pet) for cardiac imaging

Dosage: SOLUTION

More Information on Dosage

FLYRCADO family patents

Family Patents

63. Genvoya patent expiration

GENVOYA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(7 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 25, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Dosing Schedule(D-173) Dec 10, 2021

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 05 November, 2015

Treatment: Treatment of hiv infection

Dosage: TABLET

How can I launch a generic of GENVOYA before it's drug patent expiration?
More Information on Dosage

GENVOYA family patents

Family Patents

64. Gilenya patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592208 NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Mar, 2032

(7 years from now)

US9592208

(Pediatric)

NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Sep, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-106) Jul 20, 2014
New Chemical Entity Exclusivity(NCE) Sep 21, 2015
New Patient Population(NPP) May 11, 2021
New Strength(NS) May 11, 2021
Pediatric Exclusivity(PED) Nov 11, 2021

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

NCE-1 date: 11 November, 2020

Market Authorisation Date: 11 May, 2018

Treatment: Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod

Dosage: CAPSULE

How can I launch a generic of GILENYA before it's drug patent expiration?
More Information on Dosage

GILENYA family patents

Family Patents

65. Gonitro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101592 POHL BOSKAMP Stabilized granules containing glyceryl trinitrate
Mar, 2032

(7 years from now)




Drugs and Companies using NITROGLYCERIN ingredient

Market Authorisation Date: 08 June, 2016

Treatment: NA

Dosage: POWDER

More Information on Dosage

GONITRO family patents

Family Patents

66. Harvoni patent expiration

HARVONI's oppositions filed in EPO
HARVONI IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393256 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(7 years from now)

US10456414 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-153) Nov 12, 2018
New Indication(I-718) Nov 12, 2018
New Indication(I-719) Nov 12, 2018
New Indication(I-720) Nov 12, 2018
New Dosing Schedule(D-158) Feb 12, 2019
New Dosing Schedule(D-159) Feb 12, 2019
New Dosing Schedule(D-160) Feb 12, 2019
New Chemical Entity Exclusivity(NCE) Oct 10, 2019
New Patient Population(NPP) Apr 07, 2020
New Dosing Schedule(D-177) Nov 15, 2022
Orphan Drug Exclusivity(ODE) Apr 07, 2024
ODE*(ODE*) Aug 28, 2026
Orphan Drug Exclusivity(ODE-136) Apr 07, 2024
Pediatric Exclusivity(PED) Oct 07, 2024
Orphan Drug Exclusivity(ODE-262) Aug 28, 2026
Orphan Drug Exclusivity(ODE-263) Aug 28, 2026
Orphan Drug Exclusivity(ODE-264) Aug 28, 2026

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

NCE-1 date: 08 October, 2023

Market Authorisation Date: 28 August, 2019

Treatment: For the treatment of hepatitis c

Dosage: TABLET; PELLETS

More Information on Dosage

HARVONI family patents

Family Patents

67. Hepzato patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098997 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(7 years from now)

US11241522 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(7 years from now)

US11633528 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(7 years from now)

US10369264 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(7 years from now)

US10569004 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(7 years from now)

US11083831 DELCATH SYSTEMS INC Filter and frame apparatus and method of use
Dec, 2032

(8 years from now)

US11833286 DELCATH SYSTEMS INC Filter and frame apparatus and method of use
Dec, 2032

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 14, 2026
Orphan Drug Exclusivity(ODE-438) Aug 14, 2030

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 August, 2023

Treatment: A percutaneous hepatic perfusion procedure for treating a patient with uveal melanoma with unresectable hepatic metastases; A method of treating a patient with uveal melanoma with unresectable hepatic...

Dosage: POWDER

More Information on Dosage

HEPZATO family patents

Family Patents

68. Ilevro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921337 HARROW EYE Carboxyvinyl polymer-containing nanoparticle suspensions
Mar, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 16, 2015

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 16 October, 2012

Treatment: NA

Dosage: SUSPENSION/DROPS

How can I launch a generic of ILEVRO before it's drug patent expiration?
More Information on Dosage

ILEVRO family patents

Family Patents

69. Imvexxy patent expiration

IMVEXXY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835487 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(7 years from now)

US11351182 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(7 years from now)

US11497709 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(7 years from now)

US11304959 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(7 years from now)

US9289382 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(7 years from now)

US11241445 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(7 years from now)

US11246875 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(7 years from now)

US10806697 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(7 years from now)

US10537581 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 29, 2021

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 29 May, 2018

Treatment: Treatment of a symptom of vulvar and vaginal atrophy

Dosage: INSERT

How can I launch a generic of IMVEXXY before it's drug patent expiration?
More Information on Dosage

IMVEXXY family patents

Family Patents

70. Inbrija patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685442 MERZ PHARMS Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(7 years from now)

US9393210 MERZ PHARMS Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(7 years from now)

US8545878 MERZ PHARMS Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(7 years from now)

US8945612 MERZ PHARMS Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 21, 2021

Drugs and Companies using LEVODOPA ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER

More Information on Dosage

INBRIJA family patents

Family Patents

71. Inrebic patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10391094 BRISTOL-MYERS Compositions and methods for treating myelofibrosis
Jun, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 16, 2024
Orphan Drug Exclusivity(ODE-259) Aug 16, 2026

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

NCE-1 date: 17 August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis

Dosage: CAPSULE

More Information on Dosage

INREBIC family patents

Family Patents

72. Ionsys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8781571 THE MEDICINES CO Switch validation circuit and method
Mar, 2032

(7 years from now)

US8428708 THE MEDICINES CO Self-test for analgesic product
May, 2032

(7 years from now)

US8428709 THE MEDICINES CO Current control for electrotransport drug delivery
Jun, 2032

(7 years from now)




Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: Method for iontophoretic transdermal delivery of fentanyl hydrochloride

Dosage: SYSTEM

More Information on Dosage

IONSYS family patents

Family Patents

73. Isentress Hd patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10772888 MSD SUB MERCK Solid pharmaceutical compositions containing an integrase inhibitor
Mar, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) May 26, 2020
New Patient Population(NPP) Nov 22, 2020
Pediatric Exclusivity(PED) May 22, 2021

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

NCE-1 date: 22 May, 2020

Market Authorisation Date: 12 October, 2007

Treatment: Treatment of hiv-1 infection

Dosage: TABLET

How can I launch a generic of ISENTRESS HD before it's drug patent expiration?
More Information on Dosage

ISENTRESS HD family patents

Family Patents

74. Joenja patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8653092 PHARMING Tetrahydro-pyrido-pyrimidine derivatives
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 24, 2028
Orphan Drug Exclusivity(ODE-430) Mar 24, 2030

Drugs and Companies using LENIOLISIB PHOSPHATE ingredient

NCE-1 date: 25 March, 2027

Market Authorisation Date: 24 March, 2023

Treatment: NA

Dosage: TABLET

More Information on Dosage

JOENJA family patents

Family Patents

75. Jornay Pm patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10292937 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US9283214 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US9023389 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US10881618 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US9028868 IRONSHORE PHARMS Methods and compositions for treatment of attention deficit disorder
Mar, 2032

(7 years from now)

US9034902 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US8916588 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US9603809 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US10617651 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US10182995 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US8927010 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US11911518 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US11241391 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US11241392 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US10905652 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US9498447 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 08, 2021

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2018

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

JORNAY PM family patents

Family Patents

76. Korlym patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842801 CORCEPT THERAP Optimizing mifepristone absorption
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 17, 2015
Orphan Drug Exclusivity(ODE) Feb 17, 2019
Orphan Drug Exclusivity(ODE-22) Feb 17, 2019

Drugs and Companies using MIFEPRISTONE ingredient

Market Authorisation Date: 17 February, 2012

Treatment: Treating cushing's syndrome

Dosage: TABLET

How can I launch a generic of KORLYM before it's drug patent expiration?
More Information on Dosage

KORLYM family patents

Family Patents

77. Kuvan patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216178 BIOMARIN PHARM Dry blend formulation of tetrahydrobiopterin
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 13, 2012
Orphan Drug Exclusivity(ODE) Dec 13, 2014
New Patient Population(NPP) Apr 23, 2017
Pediatric Exclusivity(PED) Oct 23, 2017

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2013

Treatment: NA

Dosage: POWDER

How can I launch a generic of KUVAN before it's drug patent expiration?
More Information on Dosage

KUVAN family patents

Family Patents

78. Lazanda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731869 BTCP PHARMA Container
Jan, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jun 30, 2014

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 30 June, 2011

Treatment: NA

Dosage: SPRAY, METERED

More Information on Dosage

LAZANDA family patents

Family Patents

79. Levemir Flexpen patent expiration

LEVEMIR FLEXPEN's oppositions filed in EPO
LEVEMIR FLEXPEN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265893 NOVO NORDISK INC Injection button
Sep, 2032

(7 years from now)




Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

LEVEMIR FLEXPEN family patents

Family Patents

80. Levemir Flextouch patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)




Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

LEVEMIR FLEXTOUCH family patents

Family Patents

81. Levothyroxine Sodium patent expiration

LEVOTHYROXINE SODIUM IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168239 FRESENIUS KABI USA Levothyroxine formulations
Aug, 2032

(7 years from now)

US9168238 FRESENIUS KABI USA Levothyroxine formulations
Aug, 2032

(7 years from now)

US9006289 FRESENIUS KABI USA Levothyroxine formulations
Oct, 2032

(7 years from now)




Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 24 June, 2011

Treatment: NA

Dosage: POWDER

How can I launch a generic of LEVOTHYROXINE SODIUM before it's drug patent expiration?
More Information on Dosage

LEVOTHYROXINE SODIUM family patents

Family Patents

82. Livmarli patent expiration

Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10512657 MIRUM Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
Oct, 2032

(7 years from now)

US11376251 MIRUM Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
Oct, 2032

(7 years from now)

US11229661 MIRUM Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Mar 13, 2026
New Chemical Entity Exclusivity(NCE) Sep 29, 2026
New Indication(I-938) Mar 13, 2027
Orphan Drug Exclusivity(ODE-379) Sep 29, 2028
Orphan Drug Exclusivity(ODE-429) Mar 13, 2030
ODE*(ODE*) Mar 13, 2031
Orphan Drug Exclusivity(ODE-471) Mar 13, 2031
Orphan Drug Exclusivity(ODE-490) Jul 24, 2031

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: 29 September, 2025

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (pfic); Treatment of cholestatic pruritus in patients 3 months of age and ol...

Dosage: SOLUTION

More Information on Dosage

LIVMARLI family patents

Family Patents

83. Livtencity patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11684632 TAKEDA PHARMS USA Maribavir isomers, compositions, methods of making and methods of using
Jan, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 23, 2026
Orphan Drug Exclusivity(ODE-388) Nov 23, 2028

Drugs and Companies using MARIBAVIR ingredient

NCE-1 date: 23 November, 2025

Market Authorisation Date: 23 November, 2021

Treatment: Treatment of patients with post-transplant cytomegalovirus (cmv) infection/disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet, where the patient is a stem cell, ...

Dosage: TABLET

More Information on Dosage

LIVTENCITY family patents

Family Patents

84. Lokelma patent expiration

LOKELMA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10413569 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(7 years from now)

US11406662 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(7 years from now)

US8802152 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Apr, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335432 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(7 years from now)

US9861658 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(7 years from now)

US9844567 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(7 years from now)

US10398730 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(7 years from now)

US8808750 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-261) Apr 24, 2023
New Chemical Entity Exclusivity(NCE) May 18, 2023

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

NCE-1 date: 18 May, 2022

Market Authorisation Date: 18 May, 2018

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION

How can I launch a generic of LOKELMA before it's drug patent expiration?
More Information on Dosage

LOKELMA family patents

Family Patents

85. Lonhala Magnair Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168556 SUMITOMO PHARMA AM Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer
Sep, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 05, 2020

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

LONHALA MAGNAIR KIT family patents

Family Patents

86. Lybalvi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778960 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2026

Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient

NCE-1 date: 28 May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain

Dosage: TABLET

More Information on Dosage

LYBALVI family patents

Family Patents

87. Mavyret patent expiration

MAVYRET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8648037 ABBVIE Macrocyclic proline derived HCV serine protease inhibitors
Jan, 2032

(7 years from now)

US8937150 ABBVIE Anti-viral compounds
May, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648037

(Pediatric)

ABBVIE Macrocyclic proline derived HCV serine protease inhibitors
Jul, 2032

(7 years from now)

US8937150

(Pediatric)

ABBVIE Anti-viral compounds
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-230) Aug 06, 2021
New Patient Population(NPP) Apr 30, 2022
New Chemical Entity Exclusivity(NCE) Aug 03, 2022
New Dosing Schedule(D-175) Sep 26, 2022
M(M-259) Apr 10, 2023
Orphan Drug Exclusivity(ODE-232) Apr 30, 2026
Orphan Drug Exclusivity(ODE-233) Apr 30, 2026
Orphan Drug Exclusivity(ODE-372) Jun 10, 2028
Pediatric Exclusivity(PED) Dec 10, 2028

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: 11 December, 2027

Market Authorisation Date: 10 June, 2021

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg

Dosage: PELLETS; TABLET

More Information on Dosage

MAVYRET family patents

Family Patents

88. Mayzent patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12071402 NOVARTIS Immunosuppressant formulations
Jan, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 26, 2024
M(M-274) Mar 01, 2025

Drugs and Companies using SIPONIMOD ingredient

NCE-1 date: 27 March, 2023

Market Authorisation Date: 26 March, 2019

Treatment: NA

Dosage: TABLET

How can I launch a generic of MAYZENT before it's drug patent expiration?
More Information on Dosage

MAYZENT family patents

Family Patents

89. Mekinist patent expiration

MEKINIST's oppositions filed in EPO
Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9155706 NOVARTIS Pharmaceutical composition
Jan, 2032

(7 years from now)

US8580304 NOVARTIS Pharmaceutical composition
Jan, 2032

(7 years from now)

US9271941 NOVARTIS Pharmaceutical composition
Jan, 2032

(7 years from now)

US9399021 NOVARTIS Pharmaceutical composition
Jan, 2032

(7 years from now)

US9271941

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(7 years from now)

US9399021

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(7 years from now)

US8580304

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(7 years from now)

US9155706

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-678) Jan 08, 2017
New Chemical Entity Exclusivity(NCE) May 29, 2018
M(M-170) Nov 20, 2018
Orphan Drug Exclusivity(ODE) May 29, 2020
Orphan Drug Exclusivity(ODE-48) May 29, 2020
New Indication(I-745) Jun 22, 2020
Orphan Drug Exclusivity(ODE-57) Jan 08, 2021
New Indication(I-778) Apr 30, 2021
New Indication(I-781) May 04, 2021
M(M-246) Oct 06, 2022
Orphan Drug Exclusivity(ODE-148) Jun 22, 2024
Orphan Drug Exclusivity(ODE-182) Apr 30, 2025
Orphan Drug Exclusivity(ODE-183) May 04, 2025
New Indication(I-895) Jun 22, 2025
Pediatric Exclusivity(PED) Sep 16, 2026
New Indication(I-908) Mar 16, 2026
New Product(NP) Mar 16, 2026
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Treatment: NA

Dosage: TABLET

More Information on Dosage

MEKINIST family patents

Family Patents

90. Minocin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11944634 REMPEX Tetracycline compositions
Oct, 2032

(7 years from now)




Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 01 January, 1982

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of MINOCIN before it's drug patent expiration?
More Information on Dosage

MINOCIN family patents

Family Patents

91. Movantik patent expiration

MOVANTIK's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9012469 VALINOR Crystalline naloxol-peg conjugate
Apr, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 16, 2019

Drugs and Companies using NALOXEGOL OXALATE ingredient

NCE-1 date: 16 September, 2018

Market Authorisation Date: 16 September, 2014

Treatment: NA

Dosage: TABLET

How can I launch a generic of MOVANTIK before it's drug patent expiration?
More Information on Dosage

MOVANTIK family patents

Family Patents

92. Neoprofen patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8415337 RECORDATI RARE Ibuprofen compositions and methods of making same
Mar, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Apr 13, 2013

Drugs and Companies using IBUPROFEN LYSINE ingredient

Market Authorisation Date: 13 April, 2006

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of NEOPROFEN before it's drug patent expiration?
More Information on Dosage

NEOPROFEN family patents

Family Patents

93. Netspot patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9375498 AAA USA INC Process for the preparation of complexes of 68Ga
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 01, 2021
Orphan Drug Exclusivity(ODE) Jun 01, 2023
Orphan Drug Exclusivity(ODE-120) Jun 01, 2023

Drugs and Companies using GALLIUM DOTATATE GA-68 ingredient

NCE-1 date: 01 June, 2020

Market Authorisation Date: 01 June, 2016

Treatment: NA

Dosage: POWDER

More Information on Dosage

NETSPOT family patents

Family Patents

94. Neupro patent expiration

NEUPRO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925150 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Mar, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 09, 2012
New Indication(I-646) Apr 02, 2015
New Indication(I-647) Apr 02, 2015

Drugs and Companies using ROTIGOTINE ingredient

NCE-1 date: 10 May, 2011

Market Authorisation Date: 02 April, 2012

Treatment: NA

Dosage: FILM, EXTENDED RELEASE

How can I launch a generic of NEUPRO before it's drug patent expiration?
More Information on Dosage

NEUPRO family patents

Family Patents

95. Norditropin Flexpro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-572) Oct 31, 2011
Orphan Drug Exclusivity(ODE) May 31, 2014

Drugs and Companies using SOMATROPIN RECOMBINANT ingredient

Market Authorisation Date: 23 January, 2015

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

NORDITROPIN FLEXPRO family patents

Family Patents

96. Norditropin Flexpro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-572) Oct 31, 2011
Orphan Drug Exclusivity(ODE) May 31, 2014

Drugs and Companies using SOMATROPIN ingredient

Market Authorisation Date: 23 January, 2015

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

NORDITROPIN FLEXPRO family patents

Family Patents

97. Novolog Flexpen patent expiration

NOVOLOG FLEXPEN's oppositions filed in EPO
NOVOLOG FLEXPEN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265893 NOVO NORDISK INC Injection button
Sep, 2032

(7 years from now)




Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

NOVOLOG FLEXPEN family patents

Family Patents

98. Novolog Flextouch patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)




Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

NOVOLOG FLEXTOUCH family patents

Family Patents

99. Novolog Mix 70/30 Flexpen patent expiration

NOVOLOG MIX 70/30 FLEXPEN's oppositions filed in EPO
NOVOLOG MIX 70/30 FLEXPEN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265893 NOVO NORDISK INC Injection button
Sep, 2032

(7 years from now)




Drugs and Companies using INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 01 November, 2001

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

NOVOLOG MIX 70/30 FLEXPEN family patents

Family Patents

100. Nuvessa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8946276 CHEMO RESEARCH SL High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis
Jun, 2032

(7 years from now)

US9198858 CHEMO RESEARCH SL Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations
Jun, 2032

(7 years from now)

US10238634 CHEMO RESEARCH SL Aqueous-based metronidazole gel formulations
Jun, 2032

(7 years from now)

US10596155 CHEMO RESEARCH SL Aqueous-based metronidazole gel formulations
Jun, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 24, 2017

Drugs and Companies using METRONIDAZOLE ingredient

Market Authorisation Date: 24 March, 2014

Treatment: Treatment of bacterial vaginosis with metronidazole gel

Dosage: GEL

How can I launch a generic of NUVESSA before it's drug patent expiration?
More Information on Dosage

NUVESSA family patents

Family Patents

101. Odefsey patent expiration

ODEFSEY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(7 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-206) Aug 21, 2020
M(M-207) Aug 21, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 01 March, 2016

Treatment: Treatment of hiv infection

Dosage: TABLET

How can I launch a generic of ODEFSEY before it's drug patent expiration?
More Information on Dosage

ODEFSEY family patents

Family Patents

102. Ofirmev patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399012

(Pediatric)

MALLINCKRODT HOSP Reduced dose intravenous acetaminophen
Mar, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 02, 2013
M(M-196) Jan 27, 2020
Pediatric Exclusivity(PED) Jul 27, 2020

Drugs and Companies using ACETAMINOPHEN ingredient

Market Authorisation Date: 02 November, 2010

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of OFIRMEV before it's drug patent expiration?
More Information on Dosage

OFIRMEV family patents

Family Patents

103. Olinvyk patent expiration

OLINVYK's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11077098 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)

US8835488 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)

US11931350 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)

US9309234 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9642842 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 30, 2025

Drugs and Companies using OLICERIDINE ingredient

NCE-1 date: 30 October, 2024

Market Authorisation Date: 30 October, 2020

Treatment: Management of acute pain by intravenous injection

Dosage: SOLUTION

More Information on Dosage

OLINVYK family patents

Family Patents

104. Olumiant patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8158616 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
May, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089574 ELI LILLY AND CO Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
Nov, 2032

(7 years from now)

US11045474 ELI LILLY AND CO Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 31, 2023
New Indication(I-891) May 10, 2025
New Indication(I-890) Jun 13, 2025

Drugs and Companies using BARICITINIB ingredient

NCE-1 date: 31 May, 2022

Market Authorisation Date: 08 October, 2019

Treatment: Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo)

Dosage: TABLET

How can I launch a generic of OLUMIANT before it's drug patent expiration?
More Information on Dosage

OLUMIANT family patents

Family Patents

105. Ongentys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9630955 AMNEAL Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor
Dec, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: 24 April, 2024

Market Authorisation Date: 24 April, 2020

Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson’s disease experiencing off episodes

Dosage: CAPSULE

More Information on Dosage

ONGENTYS family patents

Family Patents

106. Oxbryta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10806733 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(8 years from now)

US10034879 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10017491 GLOBAL BLOOD THERAPS Compounds and uses thereof for the modulation of hemoglobin
Dec, 2032

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 25, 2024
Orphan Drug Exclusivity(ODE-281) Nov 25, 2026
Orphan Drug Exclusivity(ODE-394) Dec 17, 2028

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: 26 November, 2023

Market Authorisation Date: 14 October, 2022

Treatment: NA

Dosage: TABLET

More Information on Dosage

OXBRYTA family patents

Family Patents

107. Ozempic patent expiration

What is Ozempic?

Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.

What is the Ozempic controversy?

The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 05, 2022
New Indication(I-822) Jan 16, 2023
New Dosing Schedule(D-185) Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage

OZEMPIC family patents

Family Patents

108. Pataday Once Daily Relief patent expiration

PATADAY ONCE DAILY RELIEF IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791154 ALCON LABS INC High concentration olopatadine ophthalmic composition
May, 2032

(7 years from now)

US9533053 ALCON LABS INC High concentration olopatadine ophthalmic composition
May, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 30, 2018
Pediatric Exclusivity(PED) Jul 30, 2018

Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 2015

Treatment: Treatment of ocular itching associated with allergic conjunctivitis

Dosage: SOLUTION/DROPS

How can I launch a generic of PATADAY ONCE DAILY RELIEF before it's drug patent expiration?
More Information on Dosage

PATADAY ONCE DAILY RELIEF family patents

Family Patents

109. Pepaxto patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10285946 ONCOPEPTIDES AB Lyophilized preparations of melphalan flufenamide
Apr, 2032

(7 years from now)

US10869928 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(7 years from now)

US10322182 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(7 years from now)

US11344622 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(7 years from now)

US10543274 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 26, 2026
Orphan Drug Exclusivity(ODE-348) Feb 26, 2028

Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient

NCE-1 date: 26 February, 2025

Market Authorisation Date: 26 February, 2021

Treatment: In combination with dexamethasone to treat relapsed or refractory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received ...

Dosage: POWDER

More Information on Dosage

PEPAXTO family patents

Family Patents

110. Plenvu patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10780112 SALIX Colonoscopy-preparation
Mar, 2032

(7 years from now)

US10792306 SALIX Colonoscopy—preparation
Mar, 2032

(7 years from now)

US11529368 SALIX Colonoscopy—preparation
Mar, 2032

(7 years from now)

US10646512 SALIX Colonoscopy - preparation
Mar, 2032

(7 years from now)

US9592252 SALIX Colonoscopy—preparation
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 04, 2021

Drugs and Companies using ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE ingredient

Market Authorisation Date: 04 May, 2018

Treatment: For cleansing of the colon in preparation for colonoscopy in adults

Dosage: FOR SOLUTION

How can I launch a generic of PLENVU before it's drug patent expiration?
More Information on Dosage

PLENVU family patents

Family Patents

111. Ponvory patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9062014 VANDA PHARMS INC Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one
May, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 18 March, 2025

Market Authorisation Date: 18 March, 2021

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults

Dosage: TABLET

More Information on Dosage

PONVORY family patents

Family Patents

112. Precedex patent expiration

PRECEDEX's oppositions filed in EPO
PRECEDEX IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10016396 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(7 years from now)

US9616049 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(7 years from now)

US8338470 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(7 years from now)

US8242158 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(7 years from now)

US8455527 HOSPIRA Methods of treatment using a dexmedetomidine premix formulation
Jan, 2032

(7 years from now)

US9320712 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(7 years from now)

US8648106 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(7 years from now)

US8338470

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(7 years from now)

US8242158

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(7 years from now)

US8455527

(Pediatric)

HOSPIRA Methods of treatment using a dexmedetomidine premix formulation
Jul, 2032

(7 years from now)

US9616049

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(7 years from now)

US8648106

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(7 years from now)

US9320712

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-577) Oct 17, 2011
M(M-61) Jun 17, 2016
Pediatric Exclusivity(PED) Dec 17, 2016
New Patient Population(NPP) Dec 16, 2025

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 31 January, 2020

Treatment: Use for sedation

Dosage: INJECTABLE

How can I launch a generic of PRECEDEX before it's drug patent expiration?
More Information on Dosage

PRECEDEX family patents

Family Patents

113. Prezcobix patent expiration

PREZCOBIX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 JANSSEN PRODS Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2017

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 29 January, 2015

Treatment: NA

Dosage: TABLET

How can I launch a generic of PREZCOBIX before it's drug patent expiration?
More Information on Dosage

PREZCOBIX family patents

Family Patents

114. Proair Digihaler patent expiration

PROAIR DIGIHALER IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

US8978966 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(7 years from now)




Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER, METERED

More Information on Dosage

PROAIR DIGIHALER family patents

Family Patents

115. Proair Hfa patent expiration

PROAIR HFA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 16, 2011

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 29 October, 2004

Treatment: NA

Dosage: AEROSOL, METERED

How can I launch a generic of PROAIR HFA before it's drug patent expiration?
More Information on Dosage

PROAIR HFA family patents

Family Patents

116. Proair Respiclick patent expiration

PROAIR RESPICLICK IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

US8978966 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 12, 2018
New Patient Population(NPP) Apr 28, 2019

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER, METERED

More Information on Dosage

PROAIR RESPICLICK family patents

Family Patents

117. Prolensa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10085958 BAUSCH AND LOMB Bromfenac bioavailability
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 05, 2016

Drugs and Companies using BROMFENAC SODIUM ingredient

Market Authorisation Date: 05 April, 2013

Treatment: NA

Dosage: SOLUTION/DROPS

How can I launch a generic of PROLENSA before it's drug patent expiration?
More Information on Dosage

PROLENSA family patents

Family Patents

118. Pyrukynd patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10632114 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(7 years from now)

US9682080 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(7 years from now)

US9980961 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(7 years from now)

US9193701 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 17, 2027
Orphan Drug Exclusivity(ODE-392) Feb 17, 2029

Drugs and Companies using MITAPIVAT SULFATE ingredient

NCE-1 date: 17 February, 2026

Market Authorisation Date: 17 February, 2022

Treatment: Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method of using a pyruvate kinase activator for the t...

Dosage: TABLET

More Information on Dosage

PYRUKYND family patents

Family Patents

119. Qinlock patent expiration

Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48731 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jun, 2032

(7 years from now)

US8940756 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jun, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 15, 2025
Orphan Drug Exclusivity(ODE-298) May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: 15 May, 2024

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of gastrointestinal stromal tumor; Treatment of gastrointestinal stromal tumors

Dosage: TABLET

More Information on Dosage

QINLOCK family patents

Family Patents

120. Qulipta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8754096 ABBVIE Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-909) Apr 17, 2026
New Chemical Entity Exclusivity(NCE) Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: 28 September, 2025

Market Authorisation Date: 28 September, 2021

Treatment: Preventive treatment of migraine in adults

Dosage: TABLET

More Information on Dosage

QULIPTA family patents

Family Patents

121. Qvar 40 patent expiration

QVAR 40 IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)




Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 15 September, 2000

Treatment: NA

Dosage: AEROSOL, METERED

How can I launch a generic of QVAR 40 before it's drug patent expiration?
More Information on Dosage

QVAR 40 family patents

Family Patents

122. Qvar 80 patent expiration

QVAR 80 IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)




Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 15 September, 2000

Treatment: NA

Dosage: AEROSOL, METERED

How can I launch a generic of QVAR 80 before it's drug patent expiration?
More Information on Dosage

QVAR 80 family patents

Family Patents

123. Qvar Redihaler patent expiration

QVAR REDIHALER IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 NORTON WATERFORD Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)




Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: AEROSOL, METERED

More Information on Dosage

QVAR REDIHALER family patents

Family Patents

124. Ravicti patent expiration

RAVICTI IPR and PTAB Proceedings
Can you believe RAVICTI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9095559 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging drugs
Mar, 2032

(7 years from now)

US8404215 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging
Mar, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
NE(NE) Feb 01, 2016
Orphan Drug Exclusivity(ODE) Feb 01, 2020
Orphan Drug Exclusivity(ODE-42) Feb 01, 2020
New Patient Population(NPP) Dec 21, 2021
Orphan Drug Exclusivity(ODE-157) Apr 28, 2024

Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient

Market Authorisation Date: 01 February, 2013

Treatment: Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder

Dosage: LIQUID

How can I launch a generic of RAVICTI before it's drug patent expiration?
More Information on Dosage

RAVICTI family patents

Family Patents

125. Restasis Multidose patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8561859 ABBVIE Dispensing device
Apr, 2032

(7 years from now)




Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 December, 2002

Treatment: NA

Dosage: EMULSION

How can I launch a generic of RESTASIS MULTIDOSE before it's drug patent expiration?
More Information on Dosage

RESTASIS MULTIDOSE family patents

Family Patents

126. Rexulti patent expiration

REXULTI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10307419 OTSUKA Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-186) Sep 23, 2019
New Chemical Entity Exclusivity(NCE) Jul 10, 2020
New Patient Population(NPP) Dec 27, 2024
New Indication(I-913) May 10, 2026
Pediatric Exclusivity(PED) Nov 10, 2026
M(M-14) May 08, 2027

Drugs and Companies using BREXPIPRAZOLE ingredient

NCE-1 date: 10 November, 2025

Market Authorisation Date: 10 July, 2015

Treatment: NA

Dosage: TABLET

How can I launch a generic of REXULTI before it's drug patent expiration?
More Information on Dosage

REXULTI family patents

Family Patents

127. Rezzayo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11654196 MUNDIPHARMA Dosing regimens for echinocandin class compounds
Mar, 2032

(7 years from now)

US8722619 MUNDIPHARMA Antifungal agents and uses thereof
Mar, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 22, 2028
Orphan Drug Exclusivity(ODE-426) Mar 22, 2030
Generating Antibiotic Incentives Now(GAIN) Mar 22, 2033

Drugs and Companies using REZAFUNGIN ACETATE ingredient

NCE-1 date: 22 March, 2032

Market Authorisation Date: 22 March, 2023

Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration

Dosage: POWDER

More Information on Dosage

REZZAYO family patents

Family Patents

128. Rivive patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020343 HARM REDUCTION THERP Intranasal pharmaceutical dosage forms comprising naloxone
May, 2032

(7 years from now)

US11806428 HARM REDUCTION THERP Intranasal pharmaceutical dosage forms comprising naloxone
May, 2032

(7 years from now)




Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 July, 2023

Treatment: Use of intranasal naloxone for the treatment of opioid overdose

Dosage: SPRAY, METERED

More Information on Dosage

RIVIVE family patents

Family Patents

129. Rykindo patent expiration

RYKINDO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098882 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(7 years from now)

US10406161 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(7 years from now)

US11110094 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(7 years from now)

US9446135 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(7 years from now)

US9532991 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(7 years from now)




Drugs and Companies using RISPERIDONE ingredient

Market Authorisation Date: 13 January, 2023

Treatment: Treatment of schizophrenia in adults

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

RYKINDO family patents

Family Patents

130. Ryzodeg 70/30 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 16, 2019
New Chemical Entity Exclusivity(NCE) Sep 25, 2020

Drugs and Companies using INSULIN ASPART; INSULIN DEGLUDEC ingredient

NCE-1 date: 26 September, 2019

Market Authorisation Date: 25 September, 2015

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

RYZODEG 70/30 family patents

Family Patents

131. Saxenda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

US9132239

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
New Product(NP) Jan 25, 2017
New Patient Population(NPP) Dec 04, 2023

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 25 January, 2014

Market Authorisation Date: 23 December, 2014

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage

SAXENDA family patents

Family Patents

132. Sinuva patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8763222 INTERSECT ENT INC Methods and devices for crimping self-expanding devices
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 08, 2020

Drugs and Companies using MOMETASONE FUROATE ingredient

Market Authorisation Date: 08 December, 2017

Treatment: NA

Dosage: IMPLANT

More Information on Dosage

SINUVA family patents

Family Patents

133. Soliqua 100/33 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9821032 SANOFI-AVENTIS US Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
May, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Nov 21, 2019
New Chemical Entity Exclusivity(NCE) Jul 27, 2021

Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 21 November, 2016

Treatment: Improvement of glycemic control in type 2 diabetes mellitus patients

Dosage: SOLUTION

More Information on Dosage

SOLIQUA 100/33 family patents

Family Patents

134. Stivarga patent expiration

STIVARGA's oppositions filed in EPO
STIVARGA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9957232 BAYER HLTHCARE 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-667) Feb 25, 2016
New Chemical Entity Exclusivity(NCE) Sep 27, 2017
Orphan Drug Exclusivity(ODE) Feb 25, 2020
Orphan Drug Exclusivity(ODE-44) Feb 25, 2020
New Indication(I-744) Apr 27, 2020
Orphan Drug Exclusivity(ODE-139) Apr 27, 2024

Drugs and Companies using REGORAFENIB ingredient

NCE-1 date: 27 September, 2016

Market Authorisation Date: 27 September, 2012

Treatment: NA

Dosage: TABLET

How can I launch a generic of STIVARGA before it's drug patent expiration?
More Information on Dosage

STIVARGA family patents

Family Patents

135. Stribild patent expiration

STRIBILD's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 27, 2015
New Chemical Entity Exclusivity(NCE) Aug 27, 2017
New Indication(I-704) Dec 17, 2017
New Patient Population(NPP) Jan 27, 2020

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 27 August, 2012

Treatment: NA

Dosage: TABLET

How can I launch a generic of STRIBILD before it's drug patent expiration?
More Information on Dosage

STRIBILD family patents

Family Patents

136. Sublocade patent expiration

SUBLOCADE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921387 INDIVIOR Injectable flowable composition comprising buprenorphine
Jan, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 30, 2020

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 30 November, 2017

Treatment: Treating opioid dependency by administering buprenorphine once per month

Dosage: SOLUTION, EXTENDED RELEASE

More Information on Dosage

SUBLOCADE family patents

Family Patents

137. Symtuza patent expiration

SYMTUZA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9296769 JANSSEN PRODS Tenofovir alafenamide hemifumarate
Aug, 2032

(7 years from now)

US8754065 JANSSEN PRODS Tenofovir alafenamide hemifumarate
Aug, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 JANSSEN PRODS Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Combination(NC) Jul 17, 2021

Drugs and Companies using COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 17 July, 2018

Treatment: Treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regi...

Dosage: TABLET

How can I launch a generic of SYMTUZA before it's drug patent expiration?
More Information on Dosage

SYMTUZA family patents

Family Patents

138. Synjardy Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(7 years from now)

US10596120

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical compositions
Sep, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
New Indication(I-739) Dec 02, 2019
M(M-296) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 09 December, 2016

Treatment: Treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagli...

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of SYNJARDY XR before it's drug patent expiration?
More Information on Dosage

SYNJARDY XR family patents

Family Patents

139. Tabrecta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7767675 NOVARTIS PHARM Imidazotriazines and imidazopyrimidines as kinase inhibitors
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 06, 2025
Orphan Drug Exclusivity(ODE-291) May 06, 2027

Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient

NCE-1 date: 06 May, 2024

Market Authorisation Date: 06 May, 2020

Treatment: NA

Dosage: TABLET

More Information on Dosage

TABRECTA family patents

Family Patents

140. Tagrisso patent expiration

TAGRISSO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9732058 ASTRAZENECA 2-(2,4,5-substituted-anilino)pyrimidine compounds
Jul, 2032

(7 years from now)

US11524951 ASTRAZENECA 2-(2,4,5-substituted-anilino)pyrimidine compounds
Jul, 2032

(7 years from now)

US8946235 ASTRAZENECA 2-(2,4,5-substituted-anilino) pyrimidine compounds
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 13, 2020
New Indication(I-774) Apr 18, 2021
Orphan Drug Exclusivity(ODE) Nov 13, 2022
Orphan Drug Exclusivity(ODE-102) Nov 13, 2022
New Indication(I-853) Dec 18, 2023
Orphan Drug Exclusivity(ODE-176) Apr 18, 2025
New Indication(I-941) Feb 16, 2027
New Indication(I-952) Sep 25, 2027
Orphan Drug Exclusivity(ODE-337) Dec 18, 2027

Drugs and Companies using OSIMERTINIB MESYLATE ingredient

NCE-1 date: 14 November, 2019

Market Authorisation Date: 13 November, 2015

Treatment: Treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 l858r mutations in combination with...

Dosage: TABLET

How can I launch a generic of TAGRISSO before it's drug patent expiration?
More Information on Dosage

TAGRISSO family patents

Family Patents

141. Tasigna patent expiration

TASIGNA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9061029 NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Apr, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9061029

(Pediatric)

NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 29, 2012
New Indication(I-627) Jun 17, 2014
Orphan Drug Exclusivity(ODE) Oct 29, 2014
New Dosing Schedule(D-170) Dec 22, 2020
New Patient Population(NPP) Mar 22, 2021
Orphan Drug Exclusivity(ODE-171) Mar 22, 2025
Orphan Drug Exclusivity(ODE-172) Mar 22, 2025
Orphan Drug Exclusivity(ODE-380) Sep 23, 2028
Pediatric Exclusivity(PED) Mar 23, 2029

Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient

NCE-1 date: 23 March, 2028

Market Authorisation Date: 22 March, 2018

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml) by administering nilotinib dispersed in a fruit preparation

Dosage: CAPSULE

How can I launch a generic of TASIGNA before it's drug patent expiration?
More Information on Dosage

TASIGNA family patents

Family Patents

142. Tauvid patent expiration

TAUVID's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8932557 AVID RADIOPHARMS INC Imaging agents for detecting neurological dysfunction
May, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2025

Drugs and Companies using FLORTAUCIPIR F-18 ingredient

NCE-1 date: 28 May, 2024

Market Authorisation Date: 28 May, 2020

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

TAUVID family patents

Family Patents

143. Tavalisse patent expiration

TAVALISSE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8951504 RIGEL PHARMS (trimethoxyphenylamino) pyrimidinyl formulations
Jul, 2032

(7 years from now)

US8771648 RIGEL PHARMS (Trimethoxyphenylamino) pyrimidinyl formulations
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 17, 2023
Orphan Drug Exclusivity(ODE-174) Apr 17, 2025

Drugs and Companies using FOSTAMATINIB DISODIUM ingredient

NCE-1 date: 17 April, 2022

Market Authorisation Date: 17 April, 2018

Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment

Dosage: TABLET

How can I launch a generic of TAVALISSE before it's drug patent expiration?
More Information on Dosage

TAVALISSE family patents

Family Patents

144. Tazverik patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11052093 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Apr, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9522152 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-835) Jun 18, 2023
New Indication(I-836) Jun 18, 2023
New Chemical Entity Exclusivity(NCE) Jan 23, 2025
Orphan Drug Exclusivity(ODE-299) Jan 23, 2027
Orphan Drug Exclusivity(ODE-314) Jun 18, 2027

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

NCE-1 date: 24 January, 2024

Market Authorisation Date: 23 January, 2020

Treatment: Method of treating a lung metastasis of epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma

Dosage: TABLET

More Information on Dosage

TAZVERIK family patents

Family Patents

145. Technivie patent expiration

TECHNIVIE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8691938 ABBVIE Anti-viral compounds
Apr, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-743) Jul 24, 2018
New Product(NP) Jul 24, 2018
New Chemical Entity Exclusivity(NCE) Dec 19, 2019

Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 24 July, 2015

Treatment: NA

Dosage: TABLET

More Information on Dosage

TECHNIVIE family patents

Family Patents

146. Torisel patent expiration

TORISEL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791097 PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer
May, 2032

(7 years from now)

US8791097

(Pediatric)

PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-91) Apr 26, 2013
M(M-92) Jul 09, 2013
Pediatric Exclusivity(PED) Jan 09, 2014
Orphan Drug Exclusivity(ODE) May 30, 2014
M(M-61) May 30, 2015

Drugs and Companies using TEMSIROLIMUS ingredient

Market Authorisation Date: 30 May, 2007

Treatment: Method of treating metastatic papillary renal cell carcinoma with temsirolimus.

Dosage: SOLUTION

How can I launch a generic of TORISEL before it's drug patent expiration?
More Information on Dosage

TORISEL family patents

Family Patents

147. Tpoxx patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11890270 SIGA TECHNOLOGIES Polymorphic forms of ST-246 and methods of preparation
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 13, 2023
Orphan Drug Exclusivity(ODE-200) Jul 13, 2025

Drugs and Companies using TECOVIRIMAT ingredient

NCE-1 date: 13 July, 2022

Market Authorisation Date: 13 July, 2018

Treatment: Treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg

Dosage: CAPSULE

More Information on Dosage

TPOXX family patents

Family Patents

148. Tresiba patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 16, 2019
New Chemical Entity Exclusivity(NCE) Sep 25, 2020

Drugs and Companies using INSULIN DEGLUDEC ingredient

NCE-1 date: 26 September, 2019

Market Authorisation Date: 21 November, 2018

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

TRESIBA family patents

Family Patents

149. Trijardy Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(7 years from now)

US11564886 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(7 years from now)




Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 January, 2020

Treatment: Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer c...

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of TRIJARDY XR before it's drug patent expiration?
More Information on Dosage

TRIJARDY XR family patents

Family Patents

150. Trintellix patent expiration

TRINTELLIX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278096 TAKEDA PHARMS USA Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
Mar, 2032

(7 years from now)

US9278096

(Pediatric)

TAKEDA PHARMS USA Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
Sep, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 30, 2018
M(M-227) May 02, 2021
M(M-234) Oct 19, 2021
M(M-267) Nov 13, 2023
M(M-187) Jan 22, 2024
M(M-232) Aug 23, 2026
Pediatric Exclusivity(PED) Feb 23, 2027

Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient

NCE-1 date: 23 February, 2026

Market Authorisation Date: 30 September, 2013

Treatment: Use in the treatment of major depressive disorder to improve treatment emergent sexual dysfunction (tesd) induced by prior serotonin reuptake inhibitor treatment

Dosage: TABLET

How can I launch a generic of TRINTELLIX before it's drug patent expiration?
More Information on Dosage

TRINTELLIX family patents

Family Patents

151. Trudhesa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550036 IMPEL PHARMS Nasal drug delivery device
Sep, 2032

(7 years from now)

US10507295 IMPEL PHARMS Nasal drug delivery device
Dec, 2032

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 02, 2024

Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient

Market Authorisation Date: 02 September, 2021

Treatment: NA

Dosage: SPRAY, METERED

More Information on Dosage

TRUDHESA family patents

Family Patents

152. Trulance patent expiration

TRULANCE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11319346 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Mar, 2032

(7 years from now)

US9616097 SALIX Formulations of guanylate cyclase C agonists and methods of use
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-764) Jan 24, 2021
New Chemical Entity Exclusivity(NCE) Jan 19, 2022

Drugs and Companies using PLECANATIDE ingredient

NCE-1 date: 19 January, 2021

Market Authorisation Date: 19 January, 2017

Treatment: NA

Dosage: TABLET

How can I launch a generic of TRULANCE before it's drug patent expiration?
More Information on Dosage

TRULANCE family patents

Family Patents

153. Tukysa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9457093 SEAGEN Solid dispersions of a ERB2 (HER2) inhibitor
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 17, 2025
New Indication(I-906) Jan 19, 2026
Orphan Drug Exclusivity(ODE-309) Apr 17, 2027
Orphan Drug Exclusivity(ODE-422) Jan 19, 2030

Drugs and Companies using TUCATINIB ingredient

NCE-1 date: 17 April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer

Dosage: TABLET

More Information on Dosage

TUKYSA family patents

Family Patents

154. Tuxarin Er patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066942 MAINPOINTE Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
Jan, 2032

(7 years from now)

US9107921 MAINPOINTE Oral dosage forms for oxygen containing active agents and oxyl-containing polymers
Jan, 2032

(7 years from now)




Drugs and Companies using CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE ingredient

Market Authorisation Date: 22 June, 2015

Treatment: Treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

TUXARIN ER family patents

Family Patents

155. Twyneo patent expiration

Can you believe TWYNEO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12053546 GALDERMA LABS LP Stabilized topical formulations containing core-shell microcapsules
Jun, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jul 26, 2024

Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient

Market Authorisation Date: 26 July, 2021

Treatment: NA

Dosage: CREAM

More Information on Dosage

TWYNEO family patents

Family Patents

156. Tybost patent expiration

TYBOST's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2017
New Product(NP) Sep 24, 2017
New Patient Population(NPP) Aug 22, 2022
Orphan Drug Exclusivity(ODE-260) Aug 22, 2026

Drugs and Companies using COBICISTAT ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 24 September, 2014

Treatment: NA

Dosage: TABLET

How can I launch a generic of TYBOST before it's drug patent expiration?
More Information on Dosage

TYBOST family patents

Family Patents

157. Ubrelvy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8754096 ABBVIE Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 23, 2024

Drugs and Companies using UBROGEPANT ingredient

NCE-1 date: 24 December, 2023

Market Authorisation Date: 23 December, 2019

Treatment: Acute treatment of migraine with headache, with or without aura in adults

Dosage: TABLET

More Information on Dosage

UBRELVY family patents

Family Patents

158. Varithena patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9480652 PROVENSIS Aerosol valve
May, 2032

(7 years from now)




Drugs and Companies using POLIDOCANOL ingredient

Market Authorisation Date: 21 December, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

VARITHENA family patents

Family Patents

159. Varubi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101615 TERSERA Intravenous formulations of neurokinin-1 antagonists
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 01, 2020

Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient

NCE-1 date: 02 September, 2019

Market Authorisation Date: 25 October, 2017

Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy

Dosage: EMULSION

More Information on Dosage

VARUBI family patents

Family Patents

160. Vazalore patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9226892 PLX PHARMA pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Sep, 2032

(7 years from now)

US10646431 PLX PHARMA PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Sep, 2032

(7 years from now)

US10786444 PLX PHARMA PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Sep, 2032

(7 years from now)

US9216150 PLX PHARMA pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Sep, 2032

(7 years from now)




Drugs and Companies using ASPIRIN ingredient

Market Authorisation Date: 26 February, 2021

Treatment: Temporary reduction of fever; A method of targeting release of a non-steroidal anti-inflammatory drug (nsaid) to the small intestine of the subject when administered orally

Dosage: CAPSULE

More Information on Dosage

VAZALORE family patents

Family Patents

161. Veklury patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10065958

(Pediatric)

GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Mar, 2032

(7 years from now)

US11492353

(Pediatric)

GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Jun, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-183) Jan 21, 2025
New Patient Population(NPP) Apr 25, 2025
New Chemical Entity Exclusivity(NCE) Oct 22, 2025
M(M-301) Jul 13, 2026
Pediatric Exclusivity(PED) Jan 13, 2027

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: 13 January, 2026

Market Authorisation Date: 22 October, 2020

Treatment: NA

Dosage: POWDER; SOLUTION

More Information on Dosage

VEKLURY family patents

Family Patents

162. Vemlidy patent expiration

VEMLIDY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(7 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 11, 2019
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
M(M-255) Feb 04, 2023
M(M-266) Aug 22, 2023
New Patient Population(NPP) Oct 17, 2025

Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 10 November, 2016

Treatment: Treatment of chronic hepatitis b virus infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg; Treatment of chronic hepatitis b in adult patients

Dosage: TABLET

How can I launch a generic of VEMLIDY before it's drug patent expiration?
More Information on Dosage

VEMLIDY family patents

Family Patents

163. Venclexta patent expiration

VENCLEXTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8722657 ABBVIE Salts and crystalline forms of an apoptosis-inducing agent
Jan, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11369599 ABBVIE Melt-extruded solid dispersions containing an apoptosis-inducing agent
May, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 11, 2021
New Indication(I-782) Jun 08, 2021
M(M-228) Jun 08, 2021
New Indication(I-789) Nov 21, 2021
New Indication(I-795) May 15, 2022
Orphan Drug Exclusivity(ODE) Apr 11, 2023
Orphan Drug Exclusivity(ODE-114) Apr 11, 2023
M(M-265) Oct 16, 2023
Orphan Drug Exclusivity(ODE-185) Jun 08, 2025
Orphan Drug Exclusivity(ODE-211) Nov 21, 2025
Orphan Drug Exclusivity(ODE-239) May 15, 2026

Drugs and Companies using VENETOCLAX ingredient

NCE-1 date: 11 April, 2020

Market Authorisation Date: 11 April, 2016

Treatment: NA

Dosage: TABLET

How can I launch a generic of VENCLEXTA before it's drug patent expiration?
More Information on Dosage

VENCLEXTA family patents

Family Patents

164. Verquvo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9604948 MERCK SHARP DOHME Process for preparing substituted 5-fluoro-1H-pyrazolopyridines
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 19, 2026

Drugs and Companies using VERICIGUAT ingredient

NCE-1 date: 19 January, 2025

Market Authorisation Date: 19 January, 2021

Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and eject...

Dosage: TABLET

More Information on Dosage

VERQUVO family patents

Family Patents

165. Victoza patent expiration

VICTOZA's oppositions filed in EPO
VICTOZA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265893 NOVO NORDISK INC Injection button
Sep, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
M(M-115) Apr 06, 2015
M(M-176) Apr 22, 2019
New Indication(I-750) Aug 25, 2020
New Patient Population(NPP) Jun 17, 2022
Pediatric Exclusivity(PED) Dec 17, 2022

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 17 December, 2021

Market Authorisation Date: 25 January, 2010

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage

VICTOZA family patents

Family Patents

166. Viekira Pak (copackaged) patent expiration

VIEKIRA PAK (COPACKAGED)'s oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8691938 ABBVIE Anti-viral compounds
Apr, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492386 ABBVIE Methods for treating HCV
Sep, 2032

(7 years from now)

US8685984 ABBVIE Methods for treating HCV
Sep, 2032

(7 years from now)

US8680106 ABBVIE Methods for treating HCV
Sep, 2032

(7 years from now)

US8466159 ABBVIE Methods for treating HCV
Sep, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-163) Apr 22, 2019
New Chemical Entity Exclusivity(NCE) Dec 19, 2019

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavir...

Dosage: TABLET

More Information on Dosage

VIEKIRA PAK (COPACKAGED) family patents

Family Patents

167. Viekira Xr patent expiration

VIEKIRA XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8691938 ABBVIE Anti-viral compounds
Apr, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10201584 ABBVIE Compositions and methods for treating HCV
May, 2032

(7 years from now)

US10201541 ABBVIE Compositions and methods for treating HCV
May, 2032

(7 years from now)

US8466159 ABBVIE Methods for treating HCV
Sep, 2032

(7 years from now)

US8685984 ABBVIE Methods for treating HCV
Sep, 2032

(7 years from now)

US8680106 ABBVIE Methods for treating HCV
Sep, 2032

(7 years from now)

US8492386 ABBVIE Methods for treating HCV
Sep, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 19, 2019

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 22 July, 2016

Treatment: Treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin....

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

VIEKIRA XR family patents

Family Patents

168. Vosevi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(7 years from now)

US9868745 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(7 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(7 years from now)

US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 18, 2022

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

NCE-1 date: 18 July, 2021

Market Authorisation Date: 18 July, 2017

Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; Treatment of a...

Dosage: TABLET

More Information on Dosage

VOSEVI family patents

Family Patents

169. Vyxeos patent expiration

VYXEOS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028912 CELATOR PHARMS Method of lyophilizing liposomes
Oct, 2032

(7 years from now)

US10835492 CELATOR PHARMS Method of lyophilizing liposomes
Oct, 2032

(7 years from now)

US10166184 CELATOR PHARMS Method of lyophilizing liposomes
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 03, 2020
New Patient Population(NPP) Mar 30, 2024
Orphan Drug Exclusivity(ODE-287) Aug 03, 2024
Orphan Drug Exclusivity(ODE-350) Mar 30, 2028

Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient

Market Authorisation Date: 03 August, 2017

Treatment: Method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related chang...

Dosage: POWDER

More Information on Dosage

VYXEOS family patents

Family Patents

170. Xartemis Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741885 MALLINCKRODT INC Gastric retentive extended release pharmaceutical compositions
May, 2032

(7 years from now)

US9050335 MALLINCKRODT INC Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
May, 2032

(7 years from now)

US9468636 MALLINCKRODT INC Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
May, 2032

(7 years from now)

US8658631 MALLINCKRODT INC Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
May, 2032

(7 years from now)

US8992975 MALLINCKRODT INC Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
May, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 11, 2017

Drugs and Companies using ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 11 March, 2014

Treatment: Management of acute pain in patients requiring opioid analgesia

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

XARTEMIS XR family patents

Family Patents

171. Xcopri patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598279 SK LIFE Neurotherapeutic azole compounds
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 10, 2025

Drugs and Companies using CENOBAMATE ingredient

NCE-1 date: 10 March, 2024

Market Authorisation Date: 10 March, 2020

Treatment: NA

Dosage: TABLET

More Information on Dosage

XCOPRI family patents

Family Patents

172. Xepi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180200 FERRER INTERNACIONAL Pharmaceutical topical compositions
Jan, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 11, 2022

Drugs and Companies using OZENOXACIN ingredient

NCE-1 date: 11 December, 2021

Market Authorisation Date: 11 December, 2017

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: CREAM

More Information on Dosage

XEPI family patents

Family Patents

173. Xospata patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8969336 ASTELLAS Diamino heterocyclic carboxamide compound
Nov, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 28, 2023
Orphan Drug Exclusivity(ODE-222) Nov 28, 2025

Drugs and Companies using GILTERITINIB FUMARATE ingredient

NCE-1 date: 28 November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: NA

Dosage: TABLET

How can I launch a generic of XOSPATA before it's drug patent expiration?
More Information on Dosage

XOSPATA family patents

Family Patents

174. Xpovio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9714226 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11787771 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(7 years from now)

US10544108 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(7 years from now)

US9079865 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(7 years from now)

US11034660 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-837) Jun 22, 2023
New Chemical Entity Exclusivity(NCE) Jul 03, 2024
ODE*(ODE*) Jun 22, 2027
Orphan Drug Exclusivity(ODE-257) Jul 03, 2026
Orphan Drug Exclusivity(ODE-310) Jun 22, 2027
Orphan Drug Exclusivity(ODE-346) Dec 18, 2027

Drugs and Companies using SELINEXOR ingredient

NCE-1 date: 04 July, 2023

Market Authorisation Date: 03 July, 2019

Treatment: Xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; Xpovio is indicated in comb...

Dosage: TABLET

More Information on Dosage

XPOVIO family patents

Family Patents

175. Xultophy 100/3.6 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

US9132239

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Nov 21, 2019
New Chemical Entity Exclusivity(NCE) Sep 25, 2020
M(M-242) Aug 08, 2022

Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient

NCE-1 date: 26 September, 2019

Market Authorisation Date: 21 November, 2016

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

XULTOPHY 100/3.6 family patents

Family Patents

176. Zecuity patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9327114 TEVA BRANDED PHARM User-activated self-contained co-packaged iontophoretic drug delivery system
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jan 17, 2016

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 17 January, 2013

Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof

Dosage: SYSTEM

More Information on Dosage

ZECUITY family patents

Family Patents

177. Zelboraf patent expiration

ZELBORAF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9447089 HOFFMANN LA ROCHE Compositions and uses thereof
Jun, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 17, 2016
Orphan Drug Exclusivity(ODE) Aug 17, 2018
Orphan Drug Exclusivity(ODE-13) Aug 17, 2018
M(M-184) Aug 31, 2019
New Indication(I-757) Nov 06, 2020
Orphan Drug Exclusivity(ODE-158) Nov 06, 2024

Drugs and Companies using VEMURAFENIB ingredient

NCE-1 date: 18 August, 2015

Market Authorisation Date: 17 August, 2011

Treatment: NA

Dosage: TABLET

More Information on Dosage

ZELBORAF family patents

Family Patents

178. Zelsuvmi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10265334 LNHC Anhydrous compositions
Jul, 2032

(7 years from now)

US9289442 LNHC Topical compositions
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 05, 2029

Drugs and Companies using BERDAZIMER SODIUM ingredient

NCE-1 date: 06 January, 2028

Market Authorisation Date: 05 January, 2024

Treatment: Method of application of topical pharmaceutical composition to treat dermatological condition

Dosage: GEL

More Information on Dosage

ZELSUVMI family patents

Family Patents

179. Zerbaxa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8476425 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(7 years from now)

US8685957 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9724353 CUBIST PHARMS LLC Methods for treating intrapulmonary infections
Sep, 2032

(7 years from now)

US10028963 CUBIST PHARMS LLC Methods for treating intrapulmonary infections
Sep, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 19, 2019
Generating Antibiotic Incentives Now(GAIN) Dec 19, 2024
New Patient Population(NPP) Apr 21, 2025

Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient

NCE-1 date: 20 December, 2023

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of ventilator-associated bacterial pneumonia; Treatment of hospital-acquired bacterial pneumonia; Methods of treating bacterial illnesses

Dosage: POWDER

More Information on Dosage

ZERBAXA family patents

Family Patents

180. Zerviate patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254286 HARROW EYE Ophthalmic formulations of cetirizine and methods of use
Jul, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) May 30, 2020
Pediatric Exclusivity(PED) Nov 30, 2020

Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 May, 2017

Treatment: NA

Dosage: SOLUTION/DROPS

More Information on Dosage

ZERVIATE family patents

Family Patents

181. Zolpimist patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8236285 AYTU Buccal, polar and non-polar spray containing zolpidem
Aug, 2032

(7 years from now)




Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 19 December, 2008

Treatment: Treatment of transient insomnia

Dosage: SPRAY, METERED

More Information on Dosage

ZOLPIMIST family patents

Family Patents

182. Zubsolv patent expiration

ZUBSOLV's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259421 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(7 years from now)

US10946010 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(7 years from now)

US8940330 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(7 years from now)

US9439900 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(7 years from now)

US10874661 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(7 years from now)

US11020387 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(7 years from now)

US11433066 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(7 years from now)

US11020388 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-713) Aug 10, 2018

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 October, 2016

Treatment: Use of zubsolv for treatment of opioid dependence

Dosage: TABLET

How can I launch a generic of ZUBSOLV before it's drug patent expiration?
More Information on Dosage

ZUBSOLV family patents

Family Patents

183. Zurampic patent expiration

ZURAMPIC's oppositions filed in EPO
Can you believe ZURAMPIC received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8546436 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2020

Drugs and Companies using LESINURAD ingredient

NCE-1 date: 23 December, 2019

Market Authorisation Date: 22 December, 2015

Treatment: NA

Dosage: TABLET

More Information on Dosage

ZURAMPIC family patents

Family Patents

184. Zykadia patent expiration

ZYKADIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9309229 NOVARTIS Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
Jan, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703787 NOVARTIS Methods of using ALK inhibitors
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 29, 2019
M(M-199) May 26, 2020
Orphan Drug Exclusivity(ODE-66) Apr 29, 2021
Orphan Drug Exclusivity(ODE) May 26, 2024
ODE*(ODE*) May 26, 2024
Orphan Drug Exclusivity(ODE-145) May 26, 2024

Drugs and Companies using CERITINIB ingredient

NCE-1 date: 29 April, 2018

Market Authorisation Date: 29 April, 2014

Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)

Dosage: CAPSULE

More Information on Dosage

ZYKADIA family patents

Family Patents

List of large molecules

1. List of Tysabri large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US9316641 BIOGEN INC. Assay for JC virus antibodies
Jan, 2032

(7 years from now)

US10590454 BIOGEN INC. Methods of preventing and removing trisulfide bonds
May, 2032

(7 years from now)

US9790533 BIOGEN INC. Methods of preventing and removing trisulfide bonds
May, 2032

(7 years from now)

Ingredients: NATALIZUMAB

2. List of Eylea large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US11253572 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

US11986511 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

US11975045 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

US10888601 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

US9669069 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

US11559564 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

US10828345 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

US10130681 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

US10857205 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

US9254338 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
May, 2032

(7 years from now)

US11707506 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jun, 2032

(7 years from now)

Ingredients: AFLIBERCEPT

3. List of Avastin large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US9487809 GENENTECH, INC. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
Jan, 2032

(7 years from now)

US10513697 GENENTECH, INC. CO2 profile cultivation
Sep, 2032

(7 years from now)

Ingredients: BEVACIZUMAB

4. List of Humira large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US8708968 ABBVIE INC. Removal of needle shields from syringes and automatic injection devices
Jan, 2032

(7 years from now)

US9339610 ABBVIE INC. Removal of needle shield from syringes and automatic injection devices
Jan, 2032

(7 years from now)

US9957318 ABBVIE INC. Protein purification methods to reduce acidic species
Apr, 2032

(7 years from now)

US9062106 ABBVIE INC. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Apr, 2032

(7 years from now)

US9090688 ABBVIE INC. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Apr, 2032

(7 years from now)

US9683033 ABBVIE INC. Cell culture methods to reduce acidic species
Apr, 2032

(7 years from now)

US9522953 ABBVIE INC. Low acidic species compositions and methods for producing and using the same
Apr, 2032

(7 years from now)

US9505834 ABBVIE INC. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Apr, 2032

(7 years from now)

Ingredients: ADALIMUMAB

5. List of Actemra large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US10874677 GENENTECH, INC. Subcutaneously administered anti-IL-6 receptor antibody
Mar, 2032

(7 years from now)

US9539263 GENENTECH, INC. Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis
May, 2032

(7 years from now)

US9750752 GENENTECH, INC. Subcutaneously administered anti-IL-6 receptor antibody
Aug, 2032

(7 years from now)

Ingredients: TOCILIZUMAB

6. List of Prolia And Xgeva large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US9133493 AMGEN INC. Method for culturing mammalian cells to improve recombinant protein production
Apr, 2032

(7 years from now)

US9388447 AMGEN INC. Method for culturing mammalian cells to improve recombinant protein production
Apr, 2032

(7 years from now)

US11685772 AMGEN INC. Mammalian cell culture
Jun, 2032

(7 years from now)

US11292829 AMGEN INC. Mammalian cell culture
Jun, 2032

(7 years from now)

US11634476 AMGEN INC. Mammalian cell culture
Jun, 2032

(7 years from now)

Ingredients: DENOSUMAB

7. List of Stelara large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US9475858 JANSSEN BIOTECH, INC. Cell culture process
Jul, 2032

(7 years from now)

US8852889 JANSSEN BIOTECH, INC. Cell culture process
Jul, 2032

(7 years from now)

Ingredients: USTEKINUMAB